Back to Dashboard
BMRN · Healthcare

Biomarin Pharmaceutical Inc

USA Healthcare Filing: 2026-06-30
34/100
Smart-money confidence1 of 3 sources positive
Below average interest

No standout activity across the feeds we track.

What this band has actually done: stocks scoring 0–25 beat the S&P 500 over the next three months 39.9% of the time, across 100,496 cases since 2015. That is below a coin flip — and so is every other band, because the median stock loses to a cap-weighted index. How we measured this

Hedge funds
45
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works
Market cap
$11.9B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About BIOMARIN PHARMACEUTICAL INC

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N-…

Who's behind the signal
Every informed buyer we can see on BMRN, across all three feeds.
Hedge funds · 9
Viking Global Investors Increased +8%
Dodge & Cox Unchanged
AQR Capital Management Decreased −26%
Citadel Advisors Decreased −75%
+3 more in the full breakdown below ↓
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 7 on record
Disclosures from 2019-12-11 to 2023-03-06
The newest disclosure we hold for this stock is 2023-03-06. That is the end of our data, not necessarily the end of the trading — our bulk STOCK Act archive stops there and newer filings arrive through a separate live feed. Treat the absence of recent rows as “not covered”, not as “no trades”.
Trade date Member Chamber Action Amount
2023-03-06 Daniel S. Goldman · D-NY House Sold $1,001 - $15,000
2021-10-18 Josh Gottheimer · D-NJ House Sold $1,001 - $15,000
2020-12-30 Gilbert Ray Cisneros, Jr. · D-CA House Bought $15,001 - $50,000
2020-10-16 Josh Gottheimer · D-NJ House Bought $1,001 - $15,000
2020-09-15 Josh Gottheimer · D-NJ House Sold $1,001 - $15,000
2019-12-16 Josh Gottheimer · D-NJ House Bought $1,001 - $15,000
2019-12-11 Josh Gottheimer · D-NJ House Bought $1,001 - $15,000
Not a model pick — but on our radar. BIOMARIN PHARMACEUTICAL INC isn't in the top-10 model right now, but 9 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
9
Investors
0
New positions
2
Increasing
6
Decreasing
1
Unchanged
Price History
Loading price data...
A member of Congress bought A member sold
Return: High: Low:

Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.

Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Portfolio Allocation
How much of each investor's portfolio is allocated to BIOMARIN PHARMACEUTICAL INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell BIOMARIN PHARMACEUTICAL INC or any security.

Get the Weekly Update

Every week, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime